Monitor timeline for stockholder approval meeting (required within 75 days of June 29 closing). Upon approval, preferred stock auto-converts to common, adding shares equal to ~$6.00 per preferred share / common price at conversion → massive potential dilution at current trading levels. Track filing of definitive proxy statement and any insider selling.
Price Chart
Executive Summary
DNA X, Inc. (SONM) issued 1,346,531 shares of Series B Convertible Preferred Stock at $6.00 per share to insider entity DNA Holdings Venture Inc. in a private placement raising ~$5.0M in new cash plus cancellation of $3.1M of existing convertible promissory note debt. The preferred stock automatically converts to common upon stockholder approval, and 2,494,000 additional common shares are reserved for consulting agreements with insiders, massively diluting existing common shareholders at a company with an $8M market cap.
Key Financial Metrics
Key Facts
- 1,346,531 shares of Series B Convertible Preferred Stock issued at $6.00 per share, stated value $6.00
- Total consideration: $5.0M cash + cancellation of $3,079,185.40 of Bridge Note principal (aggregate ~$8.1M)
- Purchaser is DNA Holdings Venture Inc., a >5% stockholder and entity associated with board member Scott Walker
- Preferred stock automatically converts into common on first trading day after stockholder approval
- Conversion price $6.00 per share; no prior conversion permitted
- Company expects to issue 2,494,000 additional common shares to consultants (DNA Holdings, Scott Walker, Brock Pierce) on stockholder approval
- Company's market cap is ~$8M; offering size ($5M new cash) is 63% of current market cap
- Common stock ticker SONM — this is a meaningful equity-linked dilution event for common shareholders
Financial Impact
~$8.1M in gross proceeds ($5.0M new cash + $3.1M debt conversion) against an $8M market cap — counts as substantial. Automatic conversion at $6.00 per share of preferred into common, plus 2,494,000 shares issued to consultants, will dilute common equity heavily if approved.
Risk Factors
- Extreme dilution to common shareholders upon conversion of preferred and issuance of consultant shares
- Substantial insider-related transaction may raise governance concerns
- Low market cap ($8M) relative to offering size ($5M cash) amplifies price sensitivity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-031675 |
| Exhibit: ex10-2.htm | 0001493152-26-031675 |
| Exhibit: ex3-1.htm | 0001493152-26-031675 |
| Document: form8-k.htm | 0001493152-26-031675 |
| Document: 0001493152-26-031675-index-headers.html | 0001493152-26-031675 |
| Document: 0001493152-26-031675-index.html | 0001493152-26-031675 |
| Document: 0001493152-26-031675.txt | 0001493152-26-031675 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 8w ago | 8-K | $3.53 $4.57 | ▲ +29.50% | ▲ +29.19% | $2.96 (−16.03%) |
Aug 27, 2026 8w ago | 8-K | $3.27 $4.06 | ▲ +24.16% | ▲ +24.26% | $2.96 (−9.48%) |
Aug 19, 2026 9w ago | Press Release | $3.44 $2.96 | ▲ +13.95% | ▲ +13.95% | $2.96 (+13.95%) |
Jul 2, 2026 16w ago | 8-K | $3.75 $3.25 | ▲ +13.33% | ▲ +12.92% | $2.96 (+21.07%) |
Jun 12, 2026 19w ago | EFFECT | $4.74 $4.05 | ▲ +14.56% | ▲ +16.34% | $2.96 (+37.55%) |
Jun 4, 2026 20w ago | 8-K | $4.75 $4.21 | ▼ −11.37% | ▼ −13.23% | $2.96 (−37.68%) |
May 27, 2026 21w ago | 8-K | $4.24 $5.70 | ▼ −34.43% | ▼ −37.58% | $2.96 (+30.19%) |
Apr 30, 2026 25w ago | 8-K / 10-K/A | $4.89 $4.73 | ▲ +3.27% | ▲ +8.56% | $2.96 (+39.47%) |
Apr 14, 2026 27w ago | 8-K | $3.15 $5.10 | ▲ +61.90% | ▲ +55.86% | $2.96 (−6.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers